S100A8 and COVID-19: Of note, elevated circulating levels of S100A8/A9 of myeloid origin reportedly represent a discriminator for COVID‐19 outcome (Silvin et al., 2020), a disease that bears high cardiovascular risk in older people (Hanssen et al., 2021).